We are confident that the results of this in silico study can pave the way for subsequent laboratory studies to further elucidate the role of NIS in the pathogenesis of SS in genetically predisposed patients with HT, including the assessment of the presence, titers and frequency of anti-NIS antibodies in patients with SS and their correlation with disease severity. This evidence concerns the gene SLC5A5 and synovial sarcoma.